1. Introduction
===============

Mycotoxins are secondary metabolic products of molds, whereby the major mycotoxin-producing fungi are certain *Aspergillus, Fusarium and Penicillium* species \[[@B1-ijerph-11-01855]\]. They are produced pre- and post-harvesting under favorable environmental conditions (temperature, humidity) in a wide range of agricultural commodities \[[@B2-ijerph-11-01855],[@B3-ijerph-11-01855]\]. According to surveys, mycotoxins (in native and metabolized conjugated form) possess potentially toxic and even carcinogenic (after long-term exposure) properties \[[@B1-ijerph-11-01855],[@B2-ijerph-11-01855],[@B3-ijerph-11-01855],[@B4-ijerph-11-01855],[@B5-ijerph-11-01855],[@B6-ijerph-11-01855],[@B7-ijerph-11-01855]\]. Their impact on public health depends on the consumption of mycotoxin-contaminated processed agricultural and animal-derived products or meat \[[@B2-ijerph-11-01855],[@B4-ijerph-11-01855]\].

Sterigmatocystin (STER) is a potentially health hazardous mycotoxin, mainly produced by various *Aspergillus, Bipolaris* and *Penicillium luteum* species. As a natural contaminant, it is often detected in food and feed \[[@B8-ijerph-11-01855],[@B9-ijerph-11-01855],[@B10-ijerph-11-01855]\], while recent data indicate that exposure to STER might also occur through inhalation or direct skin contact \[[@B10-ijerph-11-01855]\]. STER, a precursor of aflatoxin biosynthesis with hepatotoxic action, is classified in Group 2B (possibly carcinogenic) by the International Agency of Research in Cancer \[[@B11-ijerph-11-01855],[@B12-ijerph-11-01855],[@B13-ijerph-11-01855]\]. According to *in vivo* as well *in vitro* studies, it was more cytotoxic than aflatoxin in human adenocarcinoma lung cells A549 and human esophageal epithelial cells Het-1A and exhibited a mutagenic potential \[[@B14-ijerph-11-01855]\].

Ochratoxin A (OTA), produced by several fungi strains of *Aspergillus* and *Penicillium,* belongs to the major classes of mycotoxins \[[@B15-ijerph-11-01855]\]. It is characterized as possibly carcinogenic to humans (Group 2B according to the IARC classification) and is found in many food commodities and animal feeds as a mixture with other mycotoxins, in its native or "disguised" and undetectable forms \[[@B7-ijerph-11-01855],[@B15-ijerph-11-01855]\]. In addition to being nephrotoxic and renal carcinogenic, adequate studies on animals revealed that it could also severely affect liver function and even lead to hepatocellular cancer \[[@B15-ijerph-11-01855],[@B16-ijerph-11-01855],[@B17-ijerph-11-01855],[@B18-ijerph-11-01855]\].

Citrinin (CTN) is mainly produced by several fungal strains belonging to the genera *Penicillium*, *Aspergillus*, and *Monascus*, including *Penicillium verrucosum* strains that also produce OTA. IARC evaluated the carcinogenic properties of CIT and classified it in Group 3 (not classifiable as to its carcinogenicity to humans) \[[@B19-ijerph-11-01855],[@B20-ijerph-11-01855]\]. Many publications indicate the frequent co-occurrence of OTA and CTN in the environment, as well as the possible involvement (after long-term exposure) of these two mycotoxins to the development of Balkan Endemic Nephropathy (BEN) \[[@B21-ijerph-11-01855],[@B22-ijerph-11-01855],[@B23-ijerph-11-01855]\]. CTN has demonstrated dose-dependent cytotoxic properties *in vitro* and a controversial genotoxic profile \[[@B19-ijerph-11-01855],[@B20-ijerph-11-01855]\].

There is a high probability for humans and animals to be perpetually exposed to mycotoxins, through an additive process, due to tissue and food chain accumulation of these substances or their metabolites. Food processing and baking does not eliminate mycotoxins completely \[[@B17-ijerph-11-01855]\]. Studies have detected 440 pM--1 nM of CIT, 0.9--1.3 nM of OTA and about 30 pM of STER, in human serum of healthy individuals through normal exposure \[[@B24-ijerph-11-01855],[@B25-ijerph-11-01855],[@B26-ijerph-11-01855],[@B27-ijerph-11-01855],[@B28-ijerph-11-01855]\]. It has been reported that fungi strains of *Aspergillus* and *Penicillium*, from which OTA, CTN and STER are mainly produced, usually coexist, increasing the likelihood that these toxins can be present at the same time in agricultural commodities \[[@B29-ijerph-11-01855]\].

The aforementioned results motivated us to investigate the *in vitro* effects of pM to μM concentrations of these three mycotoxins, individually or in combination, in the human hepatocellular cancer cell line Hep3B. Sister chromatid exchanges (SCE), mitotic divisions (mitotic index, MI), cell cycle delays (proliferation rate index, PRI) and MTT reduction served as endpoints of genotoxicity, cytotoxicity, cytostaticity and metabolic activity (cell viability), respectively. The Hep3B cell line was chosen because, as a member of hepatoma cell line group, it retains metabolic properties normally lost during culture of primary or lymphocyte cells and is therefore considered acceptable for toxicity studies \[[@B30-ijerph-11-01855],[@B31-ijerph-11-01855],[@B32-ijerph-11-01855]\].

2. Materials and Methods
========================

2.1. Chemicals
--------------

Dulbecco's MEM (high glucose), trypsin-EDTA solution, fetal bovine serum (FBS), colcemide and penicillin/streptomycin solution (10000:10000) were obtained from GIBCO (Carlsbad, CA, USA). 5-bromo-2'-deoxyuridine (BrdU) and bisbenzimide H33258 were obtained from Applichem (Darmstadt, Germany). Dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), ochratoxin A, citrinin and sterigmatocystin were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Ochratoxin A, citrinin and sterigmatocystin stock solutions were prepared in DMSO and then further diluted with complete culture medium to the desired concentrations.

2.2. Cell Culture
-----------------

Human hepatocellular carcinoma cell line Hep3B was kindly provided by Professor G. Kolios (Department of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Greece). The cells were maintained in Dulbecco's MEM supplemented with 10% FBS and 1% penicillin/streptomycin solution, in a 37 °C humidified incubator under an atmosphere of 5% CO~2~. Passages 20--30 were used for all experiments. On attaining 75%--80% confluency, the cells were trypsinized and were seeded in appropriate cell numbers depending on the type of the experiment. All experiments took place 24 h after seeding.

2.3. MTT Assay
--------------

Metabolic activity was determined by MTT assay. Cells were seeded at a density of 10^4^ cells/well in 96-well plates. Cells were treated with various concentrations of STER, OTA and CTN for 24 h and 48 h. Control cultures were treated with drug-free vehicle DMSO (0.1%). Each treatment was assessed in 8 replicate cultures, in three independent experiments. At the end of the incubation period, the medium was discarded and each well received 200 μL of fresh medium for one hour, at 37 °C. After that, 20 μL of MTT (5 mg/mL in PBS) were added to all wells, for four hours at 37 °C. Formazan crystals were dissolved by adding 100 μL 0.04 M HCL/isopropanol, for 15 min at 37 °C and the optical density was determined at 570 nm using a microplate reader (ExpertPlus, ASYS Hitech GmbH, Nordstrasse 4. A-5301 Eugendorf, Austria). Data are presented as mean of MTT reduction ± standard error (SE) between the replicates (n = 3). IC~50~ values were calculated using GraphPad Prism 5.91 (GraphPad Software, San Diego, CA, USA) and are expressed as mean IC~50~ ± standard deviation (SD).

2.4. SCE Assay
--------------

For SCE determination 2 × 10^5^ cells were used. Hep3B cells were treated with mycotoxins at concentrations ranging from 10^−12^--10^−6^ Μ and 4 μg/mL BrdU for 72 h. Untreated cells and cells treated with 0.1% DMSO served as controls. After 48h of culture 0.07 μg/ml of colcemide was added for 24h and at the end of incubation period cultures were harvested with hypotonic KCl solution and fixed in methanol-acetic acid (3:1, v/v). All treatments were studied in three independent experiments. Differential staining of sister chromatids was achieved by a modified Fluorescence Plus Giemsa (FPG) technique \[[@B33-ijerph-11-01855]\].

Scoring was performed in a blind fashion. SCE rates---a quantitative and qualitative index of genotoxicity---were evaluated in a total of 60--75 second-division metaphases for each treatment. Since the number of chromosomes in Hep3B cells varies (modal number = 60) the frequency of SCE/chromosome was determined. The proliferation rate index (PRI)---a qualitative index of cytostaticity---was calculated according to the formula: where M~1~, M~2~ and M~3+~ correspond to the number of metaphases in the first, second, and third or subsequent mitotic divisions, respectively, while N is the total number of metaphases scored \[[@B34-ijerph-11-01855]\]. A total of 500--600 cells were scored for each treatment. To determine the mitotic index (MI)---a qualitative index of cytotoxicity---a total of about 12,000 nuclei were scored for each treatment. MI was expressed as the number of metaphases per 1000 nuclei (‰).

The expected effects (EV)---as if the mycotoxins were acting independently and additively---of the combined treatments on SCE rates were estimated by the following formula: where, EV is the expected value of the combined treatment of N substances, OV is the mean observed value of each individual treatment of N substances and OV~control~ is the mean observed value of control cultures \[[@B35-ijerph-11-01855]\]. If the OV of a combined treatment is lower, similar to or greater than the EV, substances are considered to have an antagonistic, additive or synergistic effect, respectively.

2.5. Statistical Analysis
-------------------------

Data are presented as mean ± standard error of mean (SEM). SCE frequencies were logarithmically transformed prior further analysis. One way analysis of variance (ANOVA) followed by Bonferroni\'s *post hoc* test was employed for multiple comparisons and unpaired Student's t-test for individual comparisons. Statistical analysis was performed by SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All tests were two-tailed, while *p* values \< 0.01 were considered statistically significant. The statistically significant (*p* \< 0.05) differences between expected and observed values were estimated by an unpaired t-test. Additive effect is seen when there is no difference between expected and observed values. Synergism means that the observed values are significantly above the expected values and antagonism represents the exact opposite.

2.6. Coefficient of Drug Interaction (CDI) Assessment
-----------------------------------------------------

The evaluation of the nature of mycotoxin interactions when applying the MTT assay was calculated using the coefficient of drug interaction (CDI) index calculated as CDI = AB/(A × B). According to the average optical density (*OD~570~*) of each group that we obtained by performing the MTT assay, AB is the ratio of the mycotoxin combination (CTN/OTA, CTN/STER, STER/OTA, STER/OTA/CTN) to the respective control group (AB = AB~OD570~/Control AB~OD570~) in *OD~570~*; Similarly, A or B is the ratio of the single agent to the respective control group (A= A ~OD570~/Control A ~OD570~and B = B ~OD570~/ Control B ~OD570~) in *OD~570~*. Thus, CDI value \<, =, or \> than 1 indicates synergistic, additive or antagonistic interaction, respectively \[[@B23-ijerph-11-01855]\].

3. Results
==========

3.1. Effect of CTN, OTA and STER on MTT Reduction in Hep3B Cells
----------------------------------------------------------------

The effects of CTN, OTA and STER administered in a single dosage on Hep3B cells as measured by the MTT assay are shown in [Figure 1](#ijerph-11-01855-f001){ref-type="fig"}.

![MTT reduction as a measure of metabolic activity in Hep3B cells after single administration of (**A**) citrinin (CTN) (**B**) ochratoxin Α (OTA) and (**C**) sterigmatocystin (STER), for 24 h and 48 h; Bars represent mean values of every concentration at each time point, which was evaluated at three individual experiments, performing measurements at a number of 8-plicates each time (8-plicates, n = 3).](ijerph-11-01855-g001){#ijerph-11-01855-f001}

STER and CTN exhibited cell toxicity over a period of two days, causing inhibition of MTT-reducing activity in concentrations equal or higher than 10^−8^M. For OTA the same effect is obvious in concentrations higher than 10^−6^M. IC50 values for these actions are presented in [Table 1](#ijerph-11-01855-t001){ref-type="table"}. STER has the lowest IC50 in comparison with OTA and CTN for all two time points examined. Interestingly, a biphasic dose-dependent action of STER and CTN was observed at 48h, as in lower concentrations, a statistically significant increase in MTT activity was shown.
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Mean values of IC50 in micromolar (μM) ± SD for CTN, OTA, STER as determined by MTT assay, were obtained using non-linear regression of three independent experiments in 8-plicates through the GraphPad Prism 5.91 package.

             24 h        48 h
  ---------- ----------- ----------
  **CTN**    124 ± 4.4   77 ± 2.3
  **OTA**    104 ± 3.1   45 ± 1.4
  **STER**   58 ± 3.1    22 ± 0.7

3.2. Effect of CTN, OTA and STER Co-Administration on MTT Reduction in Hep3B Cells
----------------------------------------------------------------------------------

When mycotoxins were administrated in combination, marked increases in MTT metabolic activity were observed at concentrations ranging from 10^−12^to 10^−6^ Μ ([Figure 2](#ijerph-11-01855-f002){ref-type="fig"} and [Figure 3](#ijerph-11-01855-f003){ref-type="fig"}). In specific, OTA-CTN and OTA-STER co-administration caused statistically significant enhanced MTT reduction at 24 h at concentrations ≥ 10^−10^ M and at 48h at concentrations ≥ 10^−12^M ([Figure 2](#ijerph-11-01855-f002){ref-type="fig"}C,E). On the other hand, the same effect was less intense after co-exposure to CTN-STER and CTN-STER-OTA, being though statistically significant at 24 h at 10^−12^M ([Figure 2](#ijerph-11-01855-f002){ref-type="fig"}A and [Figure 3](#ijerph-11-01855-f003){ref-type="fig"}A), as OTA's addition did not modify MTT reducing activity in Hep3B cells in comparison with control cultures.

![Evaluation of MTT activity in Hep3B cells after co-administration of (**A**) CTN and STER (**C**) OTA and CTN (**E**) STER and OTΑ for 24 and 48h; Bars represent mean values of every concentration at each time point, which was evaluated at three individual experiments, performing measurements at a number of 8-plicates each time (8-plicates, n = 3). Error bars give the standard error (SE) between the replicates (n = 3). The asterisks represent statistically significant differences over the respective vehicle-receiving cells (control) (\* *p* \< 0.01). CDI values (CDI = 1 CDI\<1 and CDI\>1, shows additive, synergic and antagonistic action respectively) after co-administration of (**B**) CTN and STER (**D**) CTN and OTA (**F**) OTA and STER. Again error bars give the standard error (SE) between the replicates (n = 3).](ijerph-11-01855-g002){#ijerph-11-01855-f002}

![Evaluation of MTT activity in Hep3B cells after co-administration of (**A**) CTN, OTA and STER for 24 and 48h; Bars represent mean values of every concentration at each time point, which was evaluated at three individual experiments, performing measurements at a number of 8-plicates each time (8-plicates, n = 3). Error bars give the standard error (SE) between the replicates (n = 3). The asterisks represent statistically significant differences over the respective vehicle-receiving cells (control) (\* *p* \< 0.01). CDI values (CDI = 1 CDI \< 1 and CDI \> 1, shows additive, synergic and antagonistic action respectively) after co-administration of (**B**) CTN, OTA and STER. Again error bars give the standard error (SE) between the replicates (n = 3).](ijerph-11-01855-g003){#ijerph-11-01855-f003}

Using the coefficient of drug interaction (CDI) index, an antagonistic interaction was revealed among all the under research mycotoxins, in particular at concentrations ranging from 10^−8^to 10^−6^ Μ, observed at all exposure periods ([Figure 2](#ijerph-11-01855-f002){ref-type="fig"}b,d,f and [Figure 3](#ijerph-11-01855-f003){ref-type="fig"}b, respectively). Indeed, antagonism at this concentration range reversed the respective STER and CTN toxicity effect presented at single administration schemes, increasing MTT activity in Hep3B cells. At concentrations as low as 10^−12^ Μ all the possible mycotoxin combinations tent to show synergism in their MTT promoting effect at 48 h. The co-exposure of Hep3B cultures to OTA-CTN led to a similar synergistic effect after 24 h as it is being shown on [Figure 2](#ijerph-11-01855-f002){ref-type="fig"}D. Interestingly, OTA's addition did not affect CTN-STER interaction profile nor altered significantly MTT activity in Hep3B cells in comparison with control cultures.

3.3. Cytogenetic Effects of CTN, OTA and STER in Hep3B Cells
------------------------------------------------------------

We evaluated SCE rates, cell cycle kinetics and mitotic divisions after CTN, OTA and STER single or combined administrations. Untreated and vehicle-treated cultures (control groups) exhibit similar SCE rates (0.22 ± 0.02 SCE/chromosome *vs.* 0.20 ± 0.02 SCE/chromosome, respectively, *p* \> 0.05), mitotic divisions (MI) (46.2 ± 0.6 ‰ *vs.* 44.6 ± 1.2 ‰, respectively, *p* \> 0.05) and cell cycle kinetics (PRI) (2.21 ± 0.03 *vs.* 2.18 ± 0.03, respectively, *p* \> 0.05), indicating that the solvent did not affect the above mentioned indices.

STER alone or in combination with OTA and/or CTN caused significant increase in the number of SCE/chromosome compared with the vehicle-treated cells that except for STER + CTN co-treatment exhibited a dose-dependent character ([Figure 4](#ijerph-11-01855-f004){ref-type="fig"}A,B). At concentrations as high as 10^−6^M STER proved highly cytotoxic so we were unable to determine SCE rates in the respective single or co-treated cultures. Marked increases in SCE rates were also shown after OTA and CTN single and combined administration.

![SCE rates after (**A**) single CTN, OTA or STER administration, (**B**) CTN, OTA and STER co-administration. STER at 10^−6^M was highly cytotoxic. Bars represent mean ± SEM. All treatments were tested in three independent experiments and approximately 60--75 2nd division metaphases were scored for each treatment. The asterisks indicate statistically significant differences over vehicle-treated cells (*p* \< 0.01). Expected *versus* observed SCE rates for (**C**) OTA + CTN, (**D**) OTA + STER, (**E**) CTN + STER and (**F**) OTA + CTN + STER treatments. EV = (OV~1~ + OV~2~ + OV~3~) -- (N − 1) × OV~control~, where EV is the expected value of the combined treatment of N substances, OV is the mean observed value of each individual treatment of N substances and OV~control~ is the mean observed value in control cultures. OV = EV, implies an additive, OV \> EV, implies a synergistic and OV \< EV, implies an antagonistic effect. The asterisks indicate statistically significant differences between OV and ΕV (*p* \< 0.05).](ijerph-11-01855-g004){#ijerph-11-01855-f004}

Observed and expected mean values of SCE rates were compared in order to evaluate mycotoxins' interaction profile as a result of co-administration. A slight though statistically significant antagonistic effect is shown at concentrations ≤ 10^−8^M ([Figure 4](#ijerph-11-01855-f004){ref-type="fig"}C--F), but still the enhanced SCE frequency observed at single administration schemes is retained.

Results of MI after single and combined mycotoxin administration are summarized in [Figure 5](#ijerph-11-01855-f005){ref-type="fig"}A,B. Apart from OTA, all treatments reduced the MI at concentrations \>10^−8^M. STER and OTA + CTN + STER were the most potent MI suppressors as they significantly reduced mitotic divisions at all concentrations tested. On the other hand Hep3B exposure to OTA and OTA+STER increases the MI at concentrations ≥ 10^−1^ M ([Figure 5](#ijerph-11-01855-f005){ref-type="fig"}A,B). No significant changes were observed between combined and the respective individual treatments.

Mycotoxins' effect on the cell-cycle progression is shown in [Figure 5](#ijerph-11-01855-f005){ref-type="fig"}C,D. All treatments but OTA caused marked PRI inhibition at concentrations \>10^−1^ M. Again STER appeared highly cytotoxic at 10^−6^M, so we were unable to determine PRI in the respective single or co-treated cultures. Interestingly, Hep3B exposure to STER or OTA+CTN and OTA+CTN+STER exerted statistically significant PRI reduction at concentrations \< 10^−1^ M. No significant changes were observed between individual and combined treatments.

![MI differentiation after (**A**) single CTN, OTA or STER administration, (**B**) CTN, OTA and STER co-administration. All treatments were tested in three independent experiments and approximately 12,000 nuclei were scored for each treatment. PRI differentiation after (**C**) single CTN, OTA or STER administration, (**D**) CTN, OTA and STER co-administration. All treatments were tested in three independent experiments and approximately 500--600 metaphases were scored for each treatment. STER and STER-co-treatments at 10^−6^M were highly cytotoxic. Bars represent mean ± SEM. The asterisks indicate statistically significant differences over the respective vehicle-treated cells (*p* \< 0.01).](ijerph-11-01855-g005){#ijerph-11-01855-f005}

4. Discussion
=============

Mycotoxin effects on public health have been extensively studied since chronic exposure can lead to serious health problems, even carcinogenesis \[[@B36-ijerph-11-01855],[@B37-ijerph-11-01855]\]. It is of great importance to investigate the effects of mycotoxin mixtures rather than focus on individual mycotoxins only, since they frequently coexist. OTA and CTN are the most common concurrent contaminants. Co-occurrence of STER is also expected as fungi strains of *Aspergillus* and *Penicillium*, from which CTN, OTA and STER are mainly produced, usually coexist \[[@B29-ijerph-11-01855]\]. The genotoxic and cytotoxic potential of OTA and CTN have been reported *in vivo* and *in vitro*, whereas STER is less studied. The doses in which these toxins are commonly tested are usually from 10^−6^to 2 × 10^−4^ M. However their potency at much lower concentrations has also attracted interest, mainly for OTA, as there are indications of cytogenetic and mutagenetic activity after chronic exposure to concentrations as low as 10^−9^ to 10^−12^ M \[[@B38-ijerph-11-01855],[@B39-ijerph-11-01855],[@B40-ijerph-11-01855]\].

Thus, herein, we focus on the *in vitro* genotoxic and cytotoxic effects of STER on the human hepatocellular cancer cell line Hep3B applied at toxic and sub-toxic doses, and in single or combined OTA and/or CTN administration.

The MTT assay is widely used to study mitochondrial activity and consequently cellular metabolism. Changes in metabolic activity usually represent changes in cell viability, as a result of cytotoxic activity. STER and CTN single administration exerted clear toxicity at concentrations \>10^−9^ M and reduced the metabolic activity of Hep3B cells at a 1000-fold lower concentration than OTA. Based on IC50 values, these three mycotoxins affect Hep3B cells in the following order STER \> OTA \> CTN. Similar OTA IC~50~ values (24 h: 90 μΜ, 48 h: 30 μΜ) have been reported in hepatoma cell line HepG2 \[[@B41-ijerph-11-01855]\], while STER demonstrated a 50% reduction of neutral red uptake at 286.1 μΜ at 24 h in the same cell line \[[@B42-ijerph-11-01855]\]. The differentiation in STER's IC~50~ value can be attributed to the functional properties of Hep3B and HepG2 cells, as well as to the different solvents and determined parameters (Neutral Red: lysosomal activity, MTT: mitochondrial activity).

Cytotoxic effects and cell-cycle delays after single mycotoxin administration were also assessed through the MI and PRI analysis, which is indicative of both cytotoxic and cytostatic activity. Hep3B treatment with STER significantly suppressed the two indices. On the other hand, CTN caused minor MI and PRI inhibition, whereas OTA did not significantly affect cell progression neither exerted cytotoxic activity. Overall, these findings demonstrate STER toxicity at pM to μΜ concentrations on Hep3B cells, complying previous studies using different cytotoxicity assays, cell line models and concentrations around 0.5--6 × 10^−6^ M \[[@B43-ijerph-11-01855]\]. Concerning CTN, the results obtained from *in vitro* studies for concentrations up to 10^−4^Μ support its cytotoxic tendency \[[@B44-ijerph-11-01855]\]. For OTA there are *in vitro* reports on bovine lymphocytes, with similar doses with what we herein examine, that also confirm its cytotoxic effect \[[@B45-ijerph-11-01855]\]. Slight heterogeneity with our results may be attributed to different metabolic properties and sensitivity of each cell line model.

Effects of the three mycotoxins applied in combination---as naturally occurring---were also addressed. Interestingly, mycotoxin co-administration showed an antagonistic interaction as the inhibitory effect of single dosage was reversed resulting in increased MTT activity. These increases, however, were not confirmed in MI and PRI assays. MTT reduction is often affected from cellular, metabolic and molecular factors that just alter the mitochondrial activity and might significantly impact the evaluation and quantitation of cell viability \[[@B46-ijerph-11-01855],[@B47-ijerph-11-01855]\]. When applying the MI and PRI assays, all mycotoxin combinations showed clear cytotoxic and cytostatic activity at concentrations \>10^−9^ Μ and mainly an additive interaction. It is worth mentioning that STER-OTA-CTN co-administration had the same effect for all the concentrations examined.

To our knowledge this is the first study dealing with alterations of the MTT, MI and PRI in response to exposure to mycotoxin combinations, *i.e.*, STER with OTA and CTN, providing a better insight on the possible cytotoxic and cytostatic interactions. Previous *in vitro* reports mainly address toxicity effects of CTN-OTA co-exposure using different cytotoxicity tests. For concentrations higher than 10^−6^ M, combinations of OTA and CTN showed clear synergistic cytotoxic effects on green monkey kidney Vero cells and porcine renal cell line LLC-PK1, using the MTT assay \[[@B22-ijerph-11-01855],[@B39-ijerph-11-01855],[@B40-ijerph-11-01855]\]. In V79 hamster fibroblasts and porcine urinary bladder epithelial cells co-treatment with OTA-CTN displayed antagonism as assessed by the Neutral Red uptake assay \[[@B48-ijerph-11-01855]\]. The same combination, at doses lower than IC50 for each individual toxin, had additive cytotoxic effects on porcine kidney epithelial cells PK15 when using the Trypan Blue assay and antagonistic, resulting in significantly increased MTT-reducing activity \[[@B49-ijerph-11-01855]\]. Therefore, variation involving CTN-OTA interaction and toxic activity is not unexpected as it depends on the *in vitro* model and the cytotoxicity assay when examined at toxic or sub-toxic levels.

In our results, mycotoxins exhibited various interactions depending on the assay performed and the concentration examined. Apart from being metabolites of similar fungi genus and possessing some chemical structure similarities, examining their mechanism of action at a molecular or cellular level is essential for a better understanding of their combined effects. CTN leads to cell death after causing disruption through selective loss of cell membrane permeability. STER as a biogenetic precursor of AFL probably leads to cell deregulation and death through DNA modification. OTA preserves a complex mode of action in comparison with the others toxins. It can affect cell viability by disrupting metabolism and reducing glyconeogenesis or by causing cell deregulation and affecting membrane permeability \[[@B50-ijerph-11-01855]\]. Thus, every mycotoxin has a specific biological pathway to affect cell viability and this is probably the reason why they share a complicated interaction profile *in vitro.*

Finally, being aware of the fact that STER, OTA and CTN share properties capable of affecting the cell genome, we employed the SCE assay in order to investigate their genotoxic potency. SCE assay is a rapid and sensitive method to detect DNA damage and evaluate possible environmental mutagens/carcinogens \[[@B51-ijerph-11-01855]\]. According to our results, Hep3B cells are sensitized to SCE induction by all mycotoxins even at the lowest concentrations (10^−12^ M). STER demonstrates a potent dose-dependent genotoxic effect while OTA is the least genotoxic. In accordance with our results is an *in vivo* study in mouse bone marrow cells, where STER induced SCE rates and chromosomal aberrations in mouse and rat bone marrow cells, in a dose-dependent manner \[[@B52-ijerph-11-01855],[@B53-ijerph-11-01855]\]. *In vitro* studies have reported a dose-dependent increase in SCE rates and chromosomal aberrations after OTA treatment \[[@B54-ijerph-11-01855]\], while an *in vivo* report has stated the opposite \[[@B55-ijerph-11-01855]\]. CTN had no effect on SCE formation in Chinese hamster ovary cells CHO-K1 and human peripheral blood lymphocytes at concentrations ranging from 5 to15 μΜ \[[@B56-ijerph-11-01855]\]. Inconsistencies with our results could be attributed to differences in experimental models and protocols.

All combined treatments increase SCE rates, from pM concentrations. Notwithstanding the fact that an antagonistic interaction was prevalent at concentrations ≤ 10^−8^M in all the co-administration schemes the already significantly enhanced SCE ratio was maintained. According to previous studies, both OTA and CTN can lead to free radical generation, while free radicals can induce DNA damage and increase SCE rates \[[@B57-ijerph-11-01855],[@B58-ijerph-11-01855],[@B59-ijerph-11-01855],[@B60-ijerph-11-01855],[@B61-ijerph-11-01855],[@B62-ijerph-11-01855]\]. OTA and STER form DNA adducts \[[@B63-ijerph-11-01855],[@B64-ijerph-11-01855]\]; some types of DNA adducts have also been correlated with SCE formation \[[@B65-ijerph-11-01855],[@B66-ijerph-11-01855]\]. Based on these findings one would expect that mycotoxin co-treatments would induce SCE rates additively (the least). However, a less-than-additive effect is evident in most combined treatments. It seems that the underlying mechanisms are quite complex and thus, in depth analysis is required.

5. Conclusions
==============

The present study is the first in the field dealing with the cytotoxic and cytogenetic effects of STER, OTA and CTN alone or in mixtures at concentrations relevant or lower than those that have been detected in human serum \[[@B24-ijerph-11-01855],[@B25-ijerph-11-01855],[@B26-ijerph-11-01855],[@B27-ijerph-11-01855],[@B28-ijerph-11-01855]\]. According to our results, Hep3B single treatment with STER displayed a highly toxic and genotoxic action in comparison with OTA and CTN. All mycotoxin schemes enhanced SCEs even at pM concentrations. STER co-treatment with OTA and/or CTN did not affect the cytogenetic effect presented at single administration despite the increased MTT reducing activity. Mycotoxin co-treatments demonstrate in general similar-to-additive or antagonistic cytotoxic and cytogenetic effects, while SCE induction seems to be regulated by complex mechanisms that need to be clarified. Based on our findings, *in vitro* exposure to STER alone or in combination with OTA and CTN, provides effects that might have an impact on public health, even at pM concentrations.
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